NCT06479070Recruiting
Prognostic Value of Measuring CtDNA in a Cohort of Patients With Stage III and IV Upper Aero-digestive Tract (UADT) Cancer , Treated With Curative RADiOtherapy With or Without Concomitant Treatment.
Prognostic Value of Measuring Circulating Tumor DNA in a Cohort of Patients With Stage III and IV UADT Cancer, Treated With Curative RADiOtherapy With or Without Concomitant Treatment.
Source: ClinicalTrials.gov · Last updated 24 Dec 2025
Brief summary (registry, in English)
Squamous cell carcinomas of the upper aero-digestive tract (SCC-UADT) represent the seventh cause of cancer and affect approximately 600,000 patients per year worldwide. The majority of UADT cancers are diagnosed at an advanced stage (70.3% at stage III and IV) and less than 60% of these patients are free of the disease at 3 years, despite aggressive multimodal local treatment by surgery and /or radiochemotherapy. The average progression-free survival (PFS) at 2 years varies between 45 and 60% depending on the studies. Tumor recurrence is most often incurable. To our knowledge, no study has demonstrated the benefit of early evaluation of the rate of decrease in ctDNA at 1 month after the end of radiotherapy alone or associated with concomitant treatment, as a predictive factor of PFS in UADT squamous cell carcinomas regardless of their HPV status. The main objective of this study is to evaluate the value of measuring the quantity of circulating tumor DNA (ctDNA) at 1 month post-treatment as a predictive factor for PFS at 24 months.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 188 (estimated)
- First submitted
- 24 Jun 2024
- Start date
- 30 Sept 2024
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- Institut de Cancérologie de Lorraine
- Diseases
- Head and neck cancer
- NCT number
- NCT06479070
What you commit to
- Study type: Interventional
- Planned participants: 188
- From 30 Sept 2024 to the primary completion date, 30 Sept 2026
- 7 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient treated with immunotherapy;
- Contraindication to radiotherapy treatment associated or not with concomitant treatment;
Other illness
- Cancer located in the cavum, ethmoidal sinus, salivary glands and skin (cutaneous squamous cell carcinoma);
- Patient who has already had cancer within 5 years (cancer other than in the UADT sphere);
- Metastatic disease (stage IVc);
Other
- Minor patient;
- Patient already treated for UADT tumor;
- OMS \> 2;
- Patient already included in another therapeutic trial;
- Pregnant woman, who may be pregnant, or currently breastfeeding;
- Persons deprived of liberty or under guardianship (including curatorship).
Who the study is looking for
- OMS 0 to 2;
- Patient suffering from UADT squamous cell carcinoma, newly diagnosed and histologically proven, regardless of the p16 protein status, naïve to any treatment for this cancer;
- Non-metastatic cancer of stages III (N1), IVa (N1 minimum) or IVb;
- Cancer localized in the oral cavity, larynx, oropharynx, hypopharynx and maxillary sinus;
- Patient for whom treatment with curative radiotherapy associated or not with concomitant treatment (Cisplatin or Cetuximab) has been validated in a multidisciplinary consultation meeting (RCP);
- Patient capable and willing to follow all study procedures in accordance with the protocol;
- Patient having understood, signed and dated the consent form communicated on the day of inclusion;
- Patient affiliated to the social security system.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Zurich (USZ) Coordinator of this site? Confirm its status | Zurich | Switzerland | Recruiting |
| CHU Besançon Coordinator of this site? Confirm its status | Besançon | France | Recruiting |
| Centre François Baclesse Coordinator of this site? Confirm its status | Caen | France | Recruiting |
| Centre Georges François Leclerc Coordinator of this site? Confirm its status | Dijon | France | Recruiting |
| Intitut Jean Godinot Coordinator of this site? Confirm its status | Reims | France | Recruiting |
| Institut de Cancérologie Strasbourg Europe Coordinator of this site? Confirm its status | Strasbourg | France | Recruiting |
| Institut de Cancérologie de Lorraine Coordinator of this site? Confirm its status | Vandœuvre-lès-Nancy | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.